Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

08:46
11/23/16
11/23
08:46
11/23/16
08:46

JPMorgan sees 'attractive opportunity' amid Eli Lilly selloff

JPMorgan analyst Chris Schott lowered his price target for Eli Lilly to $85 from $95 after the phase III trial of solanezumab missed on both primary and secondary endpoints. Beyond solanezumab, Lilly has a diverse range of new product opportunities that support 5% sales and mid-teens earnings growth, Schott tells investors in a research note. With the shares down 13% to $65.81 in pre-market trading, the analyst sees an "attractive opportunity." He keeps an Overweight rating on Lilly.

  • 04

    Dec

LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.

TODAY'S FREE FLY STORIES

LH

LabCorp

$152.30

0.68 (0.45%)

20:10
06/26/17
06/26
20:10
06/26/17
20:10
Downgrade
LabCorp rating change  »

LabCorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATXI

Avenue Therapeutics

20:06
06/26/17
06/26
20:06
06/26/17
20:06
Syndicate
Avenue Therapeutics 5.5M share IPO priced at $6.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

NXPI

NXP Semiconductors

$109.73

-0.25 (-0.23%)

20:05
06/26/17
06/26
20:05
06/26/17
20:05
Hot Stocks
NXP Semi collaborates with Shanghai Unicom, roam2free on eSIM solution »

NXP Semiconductors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

PDCE

PDC Energy

$42.88

-1.84 (-4.11%)

19:21
06/26/17
06/26
19:21
06/26/17
19:21
Hot Stocks
PDC Energy CEO 'disappointed' with Clean Air Act complaint »

Today, the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MRIN

Marin Software

$1.18

0.025 (2.17%)

19:17
06/26/17
06/26
19:17
06/26/17
19:17
Hot Stocks
Marin Software names Brad Kinnish CFO »

Marin Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

19:15
06/26/17
06/26
19:15
06/26/17
19:15
Earnings
General Motors: Previous FY17 EPS view unchanged »

General Motors said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

GM

General Motors

$34.52

0.32 (0.94%)

19:04
06/26/17
06/26
19:04
06/26/17
19:04
Hot Stocks
General Motors lowers view of 2017 U.S. car industry »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

, CST

CST Brands

$48.54

0.18 (0.37%)

18:56
06/26/17
06/26
18:56
06/26/17
18:56
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

CST

CST Brands

$48.54

0.18 (0.37%)

NSA

National Storage

$22.63

0.22 (0.98%)

ANCUF

Alimentation Couche-Tard

$48.08

1.9887 (4.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

18:52
06/26/17
06/26
18:52
06/26/17
18:52
Hot Stocks
General Motors raises expected Opel sale charge to $5.5B »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

WMT

Wal-Mart

$75.50

0.66 (0.88%)

18:43
06/26/17
06/26
18:43
06/26/17
18:43
Periodicals
Wal-Mart sued for wrongful death of Illinois Uber driver, Reuters reports »

The family of an Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHH

Armada Hoffler

$13.17

-0.07 (-0.53%)

18:34
06/26/17
06/26
18:34
06/26/17
18:34
Hot Stocks
Armada Hoffler CEO acquires 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

FB

Facebook

$153.59

-1.48 (-0.95%)

, SNAP

Snap

$17.29

-0.25 (-1.43%)

18:33
06/26/17
06/26
18:33
06/26/17
18:33
Hot Stocks
Facebook Messenger adds filters, masks to video chat »

Facebook (FB) announced…

FB

Facebook

$153.59

-1.48 (-0.95%)

SNAP

Snap

$17.29

-0.25 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

KDMN

Kadmon

$3.72

0.34 (10.06%)

18:20
06/26/17
06/26
18:20
06/26/17
18:20
Hot Stocks
Breaking Hot Stocks news story on Kadmon »

Goldentree Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$155.23

1.12 (0.73%)

, DB

Deutsche Bank

$16.88

0.24 (1.44%)

18:05
06/26/17
06/26
18:05
06/26/17
18:05
Hot Stocks
IBM selected by Digital Trade Chain Consortium to build blockchain platform »

IBM (IBM) announced that…

IBM

IBM

$155.23

1.12 (0.73%)

DB

Deutsche Bank

$16.88

0.24 (1.44%)

HSBC

HSBC

$43.91

0.55 (1.27%)

NTXFF

Natixis

$6.68

0.09 (1.37%)

SCGLY

Societe Generale

$10.39

0.095 (0.92%)

UNCFF

UniCredit

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

CE

Celanese

$93.76

0.2 (0.21%)

18:02
06/26/17
06/26
18:02
06/26/17
18:02
Hot Stocks
Celanese announces Plasticizer WVC 3800 price increases in Europe, Asia »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$29.19

0.75 (2.64%)

18:00
06/26/17
06/26
18:00
06/26/17
18:00
Hot Stocks
NAVER to acquire Xerox Research Centre Europe »

NAVER Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESES

Eco-Stim Energy

$1.12

0.01 (0.90%)

17:59
06/26/17
06/26
17:59
06/26/17
17:59
Earnings
Eco-Stim Energy sees Q2 revenue $8.4M-$9.6M, consensus $7.47M »

Eco-Stim Energy Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$145.82

-0.46 (-0.31%)

17:58
06/26/17
06/26
17:58
06/26/17
17:58
Periodicals
Apple likely acquired eye tracking company SensoMotoric, MacRumors says »

Apple appears to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NRIM

Northrim BanCorp

$30.35

-0.1 (-0.33%)

17:58
06/26/17
06/26
17:58
06/26/17
17:58
Hot Stocks
Northrim promotes Joe Schierhorn to president and CEO »

Northrim BanCorp Inc.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$24.01

-1.53 (-5.99%)

17:49
06/26/17
06/26
17:49
06/26/17
17:49
Hot Stocks
Arconic issues statement on Reynobond PE »

Arconic issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$8.92

0.39 (4.57%)

, AGO

Assured Guaranty

$41.55

0.9 (2.21%)

17:37
06/26/17
06/26
17:37
06/26/17
17:37
Hot Stocks
MBIA jumps after analyst sees debt ratings adding sale pressure »

Shares of MBIA Inc (MBI)…

MBI

MBIA

$8.92

0.39 (4.57%)

AGO

Assured Guaranty

$41.55

0.9 (2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$42.87

-1.47 (-3.32%)

, JCP

J.C. Penney

$4.67

0.11 (2.41%)

17:35
06/26/17
06/26
17:35
06/26/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Esperion (ESPR),…

ESPR

Esperion

$42.87

-1.47 (-3.32%)

JCP

J.C. Penney

$4.67

0.11 (2.41%)

FNJN

Finjan Holdings

$3.62

-0.18 (-4.74%)

NEOS

Neos Therapeutics

$7.35

0.1 (1.38%)

WDC

Western Digital

$92.66

-0.68 (-0.73%)

STX

Seagate

$42.39

-0.28 (-0.66%)

BLUE

bluebird bio

$111.10

-0.9 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

JCP

J.C. Penney

$4.67

0.11 (2.41%)

17:31
06/26/17
06/26
17:31
06/26/17
17:31
Upgrade
J.C. Penney rating change at Gordon Haskett »

J.C. Penney upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$149.70

0.85 (0.57%)

17:31
06/26/17
06/26
17:31
06/26/17
17:31
Hot Stocks
Valmont names Stephen Kaniewski CEO effective December 31, 2017 »

Valmont Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VGZ

Vista Gold

$0.87

0.02 (2.35%)

17:29
06/26/17
06/26
17:29
06/26/17
17:29
Syndicate
Breaking Syndicate news story on Vista Gold »

Vista Gold files $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.